Three independent discounted-cash-flow-style models value Halozyme Therapeutics, Inc. every trading day. 2 of 3 currently price HALO above its market price.
| Free Cash Flow model | $137.72 |
| Excess Profit model | $138.75 |
| Residual Earnings model | $7.80 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +16.9% |
| Net debt / EBITDA | 4.3× |
| Gross margin | +83.6% |
| Revenue CAGR | +28.4% |
| Cash conversion | 2.1× |
| Dividend yield | — |
| Buyback yield | +5.5% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open HALO in StockKitty